Wuxi AppTec CoWUXIF 84 EBIT per Share is $1.24 as of Mar. 2026. GuruFocus rates WUXIF with a GF Score™ of 84/100 and a GF Value™ of $12.26 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 168 Medical Diagnostics & Research companies, Wuxi AppTec Co ranks better than 61.9% on this metric.
Wuxi AppTec Co's EBIT per Share for the
three
months ended in Mar. 2026 was $0.28.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $1.24.
During the past 12 months, the average EBIT per Share Growth Rate of Wuxi AppTec Co was 47.10% per year.
During the past 3 years, the average EBIT per Share Growth Rate was 23.50% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 37.10% per year.
During the past 10 years, the average EBIT per Share Growth Rate was 33.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Wuxi AppTec Co's EBIT per Share or its related term are showing as below:
WUXIF'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: 14.2 Med: 34.7 Max: 50.5
Current: 23.5
During the past 12 years, the highest 3-Year average EBIT per Share Growth Rate of Wuxi AppTec Co was 50.50% per year. The lowest was 14.20% per year. And the median was 34.70% per year.
WUXIF's 3-Year EBIT Growth Rate is ranked better than 61.9% of 168
companies
in the Medical Diagnostics & Research industry
Industry Median: 12.75
vs WUXIF: 23.50
Wuxi AppTec Co's EBIT for the
three
months ended in Mar. 2026 was $818 Mil.
Wuxi AppTec Co (OTCPK:WUXIF) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Wuxi AppTec Co EBIT per Share Related Terms
Wuxi AppTec Co EBIT per Share Historical Data
* Premium members only.
The historical data trend for Wuxi AppTec Co's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.24
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Wuxi AppTec Co (WUXIF) has a EBIT per Share of $1.24 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Wuxi AppTec Co and its competitors. According to the industry distribution chart, Wuxi AppTec Co ranks #64 out of 168 companies in the Medical Diagnostics & Research industry, placing it in the top 38.1%.
Is Wuxi AppTec Co's EBIT per Share too high?
Wuxi AppTec Co's current EBIT per Share is $1.24. The Medical Diagnostics & Research industry median EBIT per Share is 12.75. Wuxi AppTec Co's value of $1.24 is 90.3% below this industry median. Based on the distribution chart, Wuxi AppTec Co ranks #64 out of 168 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Wuxi AppTec Co has a GF Score™ of 84/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Wuxi AppTec Co's EBIT per Share compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Wuxi AppTec Co ranks #64 out of 168 companies for EBIT per Share. This puts Wuxi AppTec Co in the upper half of its industry. The industry median EBIT per Share is 12.75. Wuxi AppTec Co's value of $1.24 is 90.3% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Medical Diagnostics & Research company?
The median EBIT per Share among Medical Diagnostics & Research companies is 12.75, based on 168 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Wuxi AppTec Co's current EBIT per Share of $1.24 is 90.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Wuxi AppTec Co and its competitors. For the Medical Diagnostics & Research industry, the median EBIT per Share is 12.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Wuxi AppTec Co's current EBIT per Share is $1.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Wuxi AppTec Co stock overvalued right now?
Based on GuruFocus' analysis, Wuxi AppTec Co (WUXIF) is currently considered Significantly Overvalued. The stock's GF Value™ is $12.26, compared to a current price of $21.19 — trading 72.8% above its estimated fair value. The current EBIT per Share is $1.24 and 90.3% below the Medical Diagnostics & Research industry median of 12.75. Wuxi AppTec Co's overall GF Score™ is 84/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Wuxi AppTec Co (WUXIF), the current EBIT per Share is $1.24 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Wuxi AppTec Co (WUXIF) Overvalued in 2026?
Based on GuruFocus' analysis, Wuxi AppTec Co stock appears to be overvalued.
The current stock price of $21.19 is trading 72.8% above its estimated GF Value™ of $12.26.
GuruFocus considers Wuxi AppTec Co to be Significantly Overvalued.
Key valuation signals for WUXIF:
EBIT per Share: $1.24
GF Value™: $12.26 vs. price of $21.19 (72.8% above fair value)
Industry Position: 90.3% below the Medical Diagnostics & Research median (#64 of 168)
No single metric tells the full story. See the WUXIF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Wuxi AppTec Co Ltd provides a portfolio of research and manufacturing services throughout the discovery, development, and manufacturing spectrum for small molecule drugs, development of computer software and databases as well as consulting services for combinatorial chemistry and pharmaceuticals. The services offered by the company include drug research and development testing, clinical research services, an end-to-end CRDMO platform for peptide, oligonucleotide, and small molecules, and integrated biology services and solutions for drug discovery. The company's reportable segments are WuXi Chemistry, which derives maximum revenue, WuXi Testing, WuXi Biology, and Others. Geographically, it derives key revenue from the United States of America, followed by PRC, Europe, and other regions.
84GF Score
Get the complete analysis for WUXIF
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WUXIF has been successfully added to your 
